These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
254 related articles for article (PubMed ID: 30188789)
1. High-Dose Chemotherapy and Blood Autologous Stem-Cell Rescue Compared With Standard Chemotherapy in Localized High-Risk Ewing Sarcoma: Results of Euro-E.W.I.N.G.99 and Ewing-2008. Whelan J; Le Deley MC; Dirksen U; Le Teuff G; Brennan B; Gaspar N; Hawkins DS; Amler S; Bauer S; Bielack S; Blay JY; Burdach S; Castex MP; Dilloo D; Eggert A; Gelderblom H; Gentet JC; Hartmann W; Hassenpflug WA; Hjorth L; Jimenez M; Klingebiel T; Kontny U; Kruseova J; Ladenstein R; Laurence V; Lervat C; Marec-Berard P; Marreaud S; Michon J; Morland B; Paulussen M; Ranft A; Reichardt P; van den Berg H; Wheatley K; Judson I; Lewis I; Craft A; Juergens H; Oberlin O; J Clin Oncol; 2018 Sep; 36(31):JCO2018782516. PubMed ID: 30188789 [TBL] [Abstract][Full Text] [Related]
2. High-Dose Chemotherapy Compared With Standard Chemotherapy and Lung Radiation in Ewing Sarcoma With Pulmonary Metastases: Results of the European Ewing Tumour Working Initiative of National Groups, 99 Trial and EWING 2008. Dirksen U; Brennan B; Le Deley MC; Cozic N; van den Berg H; Bhadri V; Brichard B; Claude L; Craft A; Amler S; Gaspar N; Gelderblom H; Goldsby R; Gorlick R; Grier HE; Guinbretiere JM; Hauser P; Hjorth L; Janeway K; Juergens H; Judson I; Krailo M; Kruseova J; Kuehne T; Ladenstein R; Lervat C; Lessnick SL; Lewis I; Linassier C; Marec-Berard P; Marina N; Morland B; Pacquement H; Paulussen M; Randall RL; Ranft A; Le Teuff G; Wheatley K; Whelan J; Womer R; Oberlin O; Hawkins DS; J Clin Oncol; 2019 Dec; 37(34):3192-3202. PubMed ID: 31553693 [TBL] [Abstract][Full Text] [Related]
3. Impact of age on safety of Busulfan-Melphalan followed by autologous hematopoietic stem-cell transplantation versus standard chemotherapy in the patients of the EURO-E.W.I.N.G. 99 and Ewing 2008 clinical trials. Choderlos de Laclos X; Risbourg S; Brennan B; Bertucci F; Gaspar N; Gelderblom H; Hawkins DS; Janeway K; Juergens H; Kasper B; Krailo MD; Cécile Le Deley M; Marec-Bérard P; McCabe MG; Metzler M; Ranft A; Strauss S; Tabone MD; Windsor R; Dirksen U; Gandemer V Eur J Cancer; 2024 Sep; 208():114229. PubMed ID: 39032218 [TBL] [Abstract][Full Text] [Related]
4. Cyclophosphamide compared with ifosfamide in consolidation treatment of standard-risk Ewing sarcoma: results of the randomized noninferiority Euro-EWING99-R1 trial. Le Deley MC; Paulussen M; Lewis I; Brennan B; Ranft A; Whelan J; Le Teuff G; Michon J; Ladenstein R; Marec-Bérard P; van den Berg H; Hjorth L; Wheatley K; Judson I; Juergens H; Craft A; Oberlin O; Dirksen U J Clin Oncol; 2014 Aug; 32(23):2440-8. PubMed ID: 24982464 [TBL] [Abstract][Full Text] [Related]
5. International randomised controlled trial for the treatment of newly diagnosed EWING sarcoma family of tumours - EURO EWING 2012 Protocol. Anderton J; Moroz V; Marec-Bérard P; Gaspar N; Laurence V; Martín-Broto J; Sastre A; Gelderblom H; Owens C; Kaiser S; Fernández-Pinto M; Fenwick N; Evans A; Strauss S; Whelan J; Wheatley K; Brennan B Trials; 2020 Jan; 21(1):96. PubMed ID: 31952545 [TBL] [Abstract][Full Text] [Related]
6. Comparison of two chemotherapy regimens in patients with newly diagnosed Ewing sarcoma (EE2012): an open-label, randomised, phase 3 trial. Brennan B; Kirton L; Marec-Bérard P; Gaspar N; Laurence V; Martín-Broto J; Sastre A; Gelderblom H; Owens C; Fenwick N; Strauss S; Moroz V; Whelan J; Wheatley K Lancet; 2022 Oct; 400(10362):1513-1521. PubMed ID: 36522207 [TBL] [Abstract][Full Text] [Related]
7. Late toxicity comparison of alkylating-based maintenance regimen with cyclophosphamide (VAC) vs ifosfamide (VAI) in Ewing sarcoma survivors treated in the randomized clinical trial Euro-EWING99-R1 in France. Corvest V; Marec-Bérard P; Lervat C; Pacquement H; Toulmonde M; Gentet JC; Laurence V; Cleirec M; Mansuy L; Bompas E; Castex MP; Taque S; Filhon B; Tabone MD; Verité C; Entz-Werle N; Saumet L; Guimard G; Pondrom M; Chevreau C; Flandrin J; Duranteau L; Rousset-Jablonski C; Brugières L; Jimenez M; Le Deley MC; Gaspar N; Fresneau B Int J Cancer; 2023 Apr; 152(8):1659-1667. PubMed ID: 36250317 [TBL] [Abstract][Full Text] [Related]
8. High-Dose Treosulfan and Melphalan as Consolidation Therapy Versus Standard Therapy for High-Risk (Metastatic) Ewing Sarcoma. Koch R; Gelderblom H; Haveman L; Brichard B; Jürgens H; Cyprova S; van den Berg H; Hassenpflug W; Raciborska A; Ek T; Baumhoer D; Egerer G; Eich HT; Renard M; Hauser P; Burdach S; Bovee J; Bonar F; Reichardt P; Kruseova J; Hardes J; Kühne T; Kessler T; Collaud S; Bernkopf M; Butterfaß-Bahloul T; Dhooge C; Bauer S; Kiss J; Paulussen M; Hong A; Ranft A; Timmermann B; Rascon J; Vieth V; Kanerva J; Faldum A; Metzler M; Hartmann W; Hjorth L; Bhadri V; Dirksen U J Clin Oncol; 2022 Jul; 40(21):2307-2320. PubMed ID: 35427190 [TBL] [Abstract][Full Text] [Related]
9. Primary disseminated multifocal Ewing sarcoma: results of the Euro-EWING 99 trial. Ladenstein R; Pötschger U; Le Deley MC; Whelan J; Paulussen M; Oberlin O; van den Berg H; Dirksen U; Hjorth L; Michon J; Lewis I; Craft A; Jürgens H J Clin Oncol; 2010 Jul; 28(20):3284-91. PubMed ID: 20547982 [TBL] [Abstract][Full Text] [Related]
10. Results of the EICESS-92 Study: two randomized trials of Ewing's sarcoma treatment--cyclophosphamide compared with ifosfamide in standard-risk patients and assessment of benefit of etoposide added to standard treatment in high-risk patients. Paulussen M; Craft AW; Lewis I; Hackshaw A; Douglas C; Dunst J; Schuck A; Winkelmann W; Köhler G; Poremba C; Zoubek A; Ladenstein R; van den Berg H; Hunold A; Cassoni A; Spooner D; Grimer R; Whelan J; McTiernan A; Jürgens H; J Clin Oncol; 2008 Sep; 26(27):4385-93. PubMed ID: 18802150 [TBL] [Abstract][Full Text] [Related]
11. Nonmetastatic Ewing family tumors: high-dose chemotherapy with stem cell rescue in poor responder patients. Results of the Italian Sarcoma Group/Scandinavian Sarcoma Group III protocol. Ferrari S; Sundby Hall K; Luksch R; Tienghi A; Wiebe T; Fagioli F; Alvegard TA; Brach Del Prever A; Tamburini A; Alberghini M; Gandola L; Mercuri M; Capanna R; Mapelli S; Prete A; Carli M; Picci P; Barbieri E; Bacci G; Smeland S Ann Oncol; 2011 May; 22(5):1221-1227. PubMed ID: 21059639 [TBL] [Abstract][Full Text] [Related]
12. Impact of gender on efficacy and acute toxicity of alkylating agent -based chemotherapy in Ewing sarcoma: secondary analysis of the Euro-Ewing99-R1 trial. van den Berg H; Paulussen M; Le Teuff G; Judson I; Gelderblom H; Dirksen U; Brennan B; Whelan J; Ladenstein RL; Marec-Berard P; Kruseova J; Hjorth L; Kühne T; Brichard B; Wheatley K; Craft A; Juergens H; Gaspar N; Le Deley MC; Eur J Cancer; 2015 Nov; 51(16):2453-64. PubMed ID: 26271204 [TBL] [Abstract][Full Text] [Related]
13. Busulfan and melphalan versus carboplatin, etoposide, and melphalan as high-dose chemotherapy for high-risk neuroblastoma (HR-NBL1/SIOPEN): an international, randomised, multi-arm, open-label, phase 3 trial. Ladenstein R; Pötschger U; Pearson ADJ; Brock P; Luksch R; Castel V; Yaniv I; Papadakis V; Laureys G; Malis J; Balwierz W; Ruud E; Kogner P; Schroeder H; de Lacerda AF; Beck-Popovic M; Bician P; Garami M; Trahair T; Canete A; Ambros PF; Holmes K; Gaze M; Schreier G; Garaventa A; Vassal G; Michon J; Valteau-Couanet D; Lancet Oncol; 2017 Apr; 18(4):500-514. PubMed ID: 28259608 [TBL] [Abstract][Full Text] [Related]
14. High-dose melphalan, etoposide, total-body irradiation, and autologous stem-cell reconstitution as consolidation therapy for high-risk Ewing's sarcoma does not improve prognosis. Meyers PA; Krailo MD; Ladanyi M; Chan KW; Sailer SL; Dickman PS; Baker DL; Davis JH; Gerbing RB; Grovas A; Herzog CE; Lindsley KL; Liu-Mares W; Nachman JB; Sieger L; Wadman J; Gorlick RG J Clin Oncol; 2001 Jun; 19(11):2812-20. PubMed ID: 11387352 [TBL] [Abstract][Full Text] [Related]
15. Etoposide plus cytarabine versus cyclophosphamide or melphalan in busulfan-based preparative regimens for autologous stem cell transplantation in adults with acute myeloid leukemia in first complete remission: a study from the Acute Leukemia Working Party of the EBMT. Sanz J; Labopin M; Pabst T; Versluis J; Van Gorkom G; Meijer E; Gedde-Dahl T; Montoro J; Arcese W; Pérez-Simón JA; Schaap N; Maertens J; Vrhovac R; Lanza F; Gorin NC; Mohty M; Ciceri F Bone Marrow Transplant; 2023 Nov; 58(11):1197-1202. PubMed ID: 37553468 [TBL] [Abstract][Full Text] [Related]
16. Autologous stem cell transplantation for adult acute myelocytic leukemia in first remission-Better outcomes after busulfan and melphalan compared with busulfan and cyclophosphamide: A retrospective study from the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation (EBMT). Gorin NC; Labopin M; Czerw T; Pabst T; Blaise D; Dumas PY; Nemet D; Arcese W; Trisolini SM; Wu D; Huynh A; Zuckerman T; Meijer E; Cagirgan S; Cornelissen J; Houhou M; Polge E; Mohty M; Nagler A Cancer; 2017 Mar; 123(5):824-831. PubMed ID: 27906458 [TBL] [Abstract][Full Text] [Related]
17. Long-term results from the multicentric European randomized phase 3 trial CWS/RMS-96 for localized high-risk soft tissue sarcoma in children, adolescents, and young adults. Sparber-Sauer M; Ferrari A; Kosztyla D; Ladenstein R; Cecchetto G; Kazanowska B; Scarzello G; Ljungman G; Milano GM; Niggli F; Alaggio R; Vokuhl C; Casanova M; Klingebiel T; Zin A; Koscielniak E; Bisogno G Pediatr Blood Cancer; 2022 Sep; 69(9):e29691. PubMed ID: 35441463 [TBL] [Abstract][Full Text] [Related]
19. Vincristine, Ifosfamide, and Doxorubicin for Initial Treatment of Ewing Sarcoma in Adults. Wagner MJ; Gopalakrishnan V; Ravi V; Livingston JA; Conley AP; Araujo D; Somaiah N; Zarzour MA; Ratan R; Wang WL; Patel SR; Lazar A; Ludwig JA; Benjamin RS Oncologist; 2017 Oct; 22(10):1271-1277. PubMed ID: 28710342 [TBL] [Abstract][Full Text] [Related]
20. Impact of high-dose busulfan plus melphalan as consolidation in metastatic Ewing tumors: a study by the Société Française des Cancers de l'Enfant. Oberlin O; Rey A; Desfachelles AS; Philip T; Plantaz D; Schmitt C; Plouvier E; Lejars O; Rubie H; Terrier P; Michon J; J Clin Oncol; 2006 Aug; 24(24):3997-4002. PubMed ID: 16921053 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]